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Pretransplant values of serum ferritin, albumin, and peripheral blood counts were previously suggested to
provide prognostic information about hematopoietic cell transplantation (HCT) outcomes. Whether these
“biomarkers” have prognostic value independent of each other and the HCT-comorbidity index (HCT-CI) is
unknown. We analyzed data from 3917 allogeneic HCT recipients at multiple sites in the United States and
Italy using multivariate models including each biomarker and the HCT-CI. Data from all sites were then
randomly divided into a training set (n ¼ 2352) to develop weights for the relevant biomarkers to be added to
the HCT-CI scores and a validation set (n ¼ 1407) to validate an augmented HCT-CI compared with the original
index. Multivariate analysis with data from one site showed that ferritin, albumin, and plateletsdnot neu-
trophils or hemoglobindwere independently associated with increased nonrelapse mortality (NRM) and
decreased overall survival. Findings were validated in data from the other sites. Subsequently, in a training set
from all sites, ferritin >2500 mg/dL (hazard ratio [HR], 1.69); albumin 3 to 3.5 g/dL (HR, 1.61) and <3.0 g/dL
(HR, 2.27); and platelets 50 to <100,000 (HR, 1.28), 20 to <50,000 (HR, 1.29), and <20,000 (HR, 1.55) were
statistically signiﬁcantly associated with NRM. Weights were assigned to these laboratory values following
the same equation used to design the original index. In the validation set, the addition of the biomarkers to
the original index to develop an augmented HCT-CI resulted in a statistically signiﬁcant increase in a higher
c-statistic estimate for prediction of NRM (P ¼ .0007). Ferritin, albumin, and platelet counts are important
prognostic markers that further reﬁne the discriminative power of the HCT-CI for transplant outcomes.
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ty for Blood and Marrow Transplantation.remains an active area of research. Certainly, disease and
treatment characteristics play a large role. Additional con-
tributions arise from the physical abilities of patients to
tolerate allogeneic HCT. The HCT-comorbidity index (HCT-CI)
was developed in 2005 to measure relationships between
medical comorbidities and nonrelapse mortality (NRM) after
HCT [1]. This index has now been validated in multi-
institutional studies [2-4]. The HCT-CI is being used to
Table 1
Patient Characteristics
All Patients
(n ¼ 3917)
n (%)
FHCRC
(n ¼ 1789)
n (%)
DFCI/GITMO
(n ¼ 2128)
n (%)
Donor
Related 1962 (50) 900 (50) 1062 (50)
Unrelated 1942 (50) 889 (50) 1053 (50)
Missing 13
Disease risk
Low 1606 (41) 740 (41) 866 (43)
High 2206 (56) 1049 (59) 1157 (57)
Missing 105
Age
<50 yr 2145 (55) 1025 (57) 1120 (53)
50 yr 1772 (45) 764 (43) 1008 (47)
Conditioning
High dose 2083 (53) 983 (55) 1100 (52)
RIC/NMA 1810 (46) 806 (45) 1004 (48)
Missing 24
Patient CMV status
 1278 (33) 773 (43) 505 (24)
þ 2596 (66) 1016 (57) 1581 (76)
Missing 42
KPS
90 1335 (34) 691 (39) 644 (33)
90-100 2402 (61) 1098 (61) 1304 (67)
Missing 180
RIC/NMA indicates reduced-intensity/nonmyeloablative conditioning; CMV,
cytomegalovirus.
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in studies examining outcomes after HCT [5,6]. Previously,
the use of objective laboratory measures within the HCT-CI
has improved its performance compared with the Charlson
comorbidity index [7]. Whether the discriminative capacity
of the HCT-CI could be further augmented by adding addi-
tional laboratory values is not known.
Previous studies have shown that a number of additional
objective laboratory “biomarkers” are of interest if pre-HCT
risk assessment is to be optimized. Serum albumin
inversely correlates with age, smoking, obesity, and hyper-
tension; serves as a marker of inﬂammatory status; and
predicts cardiovascular mortality [8,9]. Serum ferritin is an
acute phase reactant, and elevated levels suggest iron over-
load, which has been linked to post-HCT infections, hepatic,
and pulmonary complications [10-13]. Finally, cytopenias, as
represented by absolute neutrophil count (ANC), hemoglobin
(Hgb), or platelet count, could indicate poormarrow function
related to persistent malignancy or effects of prior treatment
[14-16].
Here, we analyzed the independent prognostic role of 5
readily available biomarkers (albumin, ferritin, ANC, Hgb,
and platelet count) in a large group of patients treated with
allogeneic HCT at multiple centers in the United States and
Italy. We asked two main questions: (1) Which, if any, of
these 5 biomarkers is independently associated with risks of
NRM and OS? (2) Could we integrate the relevant biomarkers
into the HCT-CI to improve its performance?
METHODS
Patients
We retrospectively collected data from 3917 patients who received
allogeneic HCT at the Fred Hutchinson Cancer Research Center (FHCRC) (n ¼
1789) and the Dana Farber Cancer Institute (DFCI) (n ¼ 716) in the United
States and at Gruppo Italiano Trapianto di Midollo Osseo (GITMO) (n ¼
1412), a network of institutions in Italy. The study was approved by the
internal review boards of the FHCRC, DFCI, and the GITMO centers. Patients
were included in the analysis if they received allogeneic HCT with either
high-dose or reduced intensity/nonmyeloablative conditioning regimens, as
previously deﬁned [17], and received either HLA-matched related or unre-
lated donor grafts. Informed consent was obtained from all patients at the
time of transplantation in accordance with the Declaration of Helsinki.
Deﬁnitions
HCT-CI scores were calculated by investigators at each institution ac-
cording to previously published criteria [1]. Physical function before HCT
was assessed using Karnofsky performance status (KPS). Low-risk diseases
included chronic myeloid leukemia in ﬁrst chronic phase, acute leukemia in
ﬁrst complete remission, myelodysplasia-refractory anemia or refractory
anemia with ringed sideroblasts, and nonmalignant hematologic diseases.
High-risk diseases included all other diagnoses.
The values of ferritin, albumin, ANC, Hgb, and platelet count obtained
closest to and up to day 10 before HCT were used in the analysis. Ferritin
concentrations were evaluated in increments of 1000, 1000 to 2500, and
2500 mg/dL consistent with cutoffs used in prior studies [18-20]. Serum
albumin concentrations were divided into 3 categories, 3.5, 3.0 to 3.5, and
<3.0 g/dL, also similar to previous studies [21,22]. ANC values were evalu-
ated in increments of >1500, 1000 to 1500, 500 to 1000, and <500/mL. Hgb
values were evaluated at cutoff values of >10, 9 to 10, and <9/mL. Platelet
counts were evaluated in 4 increments: >100,000, 50,000 to 100,000,
20,000 to 50,000, and <20,000/mL.
Statistical Analysis
Overall survival (OS) was estimated by the Kaplan-Meier method. Cu-
mulative incidence of NRM was estimated by standard methods, with
relapse and progression treated as competing risks. Cox regression models
were used to evaluate the association between each of the laboratory var-
iables and risk of NRM, adjusting for HCT-CI score (0, 1, 2, 3, 4þ), donor type
(related, unrelated), patient cytomegalovirus serology results (, þ),
regimen intensity (high-dose, reduced-intensity/nonmyeloablative), patient
age (<50, 50 years), diagnosis category (myeloid versus others), relapse
risk (low, high), and KPS. Analysis was stratiﬁed by institution. Missinginformation on any biomarker was included in the models as a separate
variable.
To ensure that any notable associations between the biomarkers of in-
terest and NRMwere reproducible across institutions, we ﬁrst assessed their
effect in a data set from a single institution (FHCRC, n ¼ 1789). Biomarkers
that showed statistically signiﬁcant independent associations with risks of
NRM in the FHCRC population were then assessed using similar statistical
methods in a larger, more heterogeneous data set from the remaining 2
institutions (DFCI and GITMO, n ¼ 2128).
In order to develop and assign weights to biomarkers, patients from all
centers were then randomly divided into 2 cohorts: 2352 (60%) patients
were assigned to a training set; the remaining 40% were assigned to a
validation set (n¼1565). Patients with missing albumin and platelet data
were then excluded from the validation set (n¼158), with a ﬁnal sample of
1407 patients contributing to the validation analysis. Integer weights for
biomarkers were derived from Cox proportional hazards modeling applied
to the training set, with NRM as the outcome of interest. Hazard ratios (HRs)
for NRM were calculated for each biomarker value, controlling for the
presence of all covariates described above, including HCT-CI scores, and
were stratiﬁed by institution. Multivariate P values for each variable were
based on adjustment for all other variables in the model. All P values were
derived from likelihood ratio statistics and were 2-sided. The adjusted HRs
were converted to integer weights according to our previously published
criteria [1]. The augmented HCT-CI score for each patient was the sum of the
score assigned to the HCT-CI plus that assigned to each biomarker value.
In the validation set, we compared the capabilities of the HCT-CI versus
the augmented model to discriminate risks of NRM and overall mortality.
Comparisons were done by computing c-statistic estimates [23] with the
same interpretation of results as previously described [1]. The c-statistic was
computed based on time-to-event data using the entire follow-up period.
Standard errors for the c-statistic and differences between c-statistics for the
original and augmented HCT-CI were evaluated in 50 bootstrap samples and
then analyzed by paired t-tests.
RESULTS
Patient Characteristics
Forty-ﬁve percent of patients were 50 years of age.
Approximately half of the patients received grafts from
HLA-matched related donors, and the remainder received
HLA-matched unrelated donor grafts. A slight majority of
patients (58%) were considered to have high-risk disease.
Fifty-four percent of patients received high-dose condition-
ing. The remaining 46% received either reduced-intensity or
nonmyeloablative regimens. A signiﬁcant number of patients
Table 2
Multivariate Analysis Showing the Associations between Biomarkers and
NRM and Survival in the FHCRC and Combined DFCI/GITMO Populations
Marker NRM Survival
HR* P* HR* P*
FHCRC
Albumin
3.5 1.0 1.0
<3.5-3.0 1.44 .002 1.45 <.0001
<3.0 1.77 <.0001 1.77 <.0001
Unknown 1.15 .38 1.19 .11
Platelets
100K 1.0 1.0
<100K-50K 1.48 .0007 1.28 .003
<50K-20K 1.49 .003 1.37 .001
<20K 1.64 .005 1.58 .0004
Unknown 0.66 .47 .48 .14
Ferritin
1000 1.0 1.0
>1000-2500 1.60 .03 1.70 .0006
>2500 2.08 .001 1.63 .007
Unknown 1.42 .03 1.44 .002
HCT-CI
0 1.0 1.0
1 1.29 .12 1.31 .02
2 1.50 .01 1.42 .001
3 2.29 <.0001 2.04 <.0001
4 2.94 <.0001 2.42 <.0001
DFCI/GITMO
Albumin
3.5 1.0 1.0
<3.5-3.0 1.60 .0001 1.36 .0005
<3.0 2.77 <.0001 2.18 <.0001
Unknown 1.61 .01 1.11 .49
Platelets
100K 1.0 1.0
<100K-50K 1.08 .56 1.02 .85
<50K-20K 1.17 .28 1.21 .06
<20K 1.38 .04 1.35 .009
Unknown .64 .10 .82 .28
Ferritin
1000 1.0 1.0
>1000-2500 1.11 .43 1.23 .02
>2500 1.60 .002 1.69 <.0001
Unknown 1.13 .33 1.12 .19
HCT-CI
0 1.0 1.0
1 1.31 .05 1.14 .19
2 1.29 .10 1.25 .04
3 1.48 .006 1.46 .0001
4 1.74 <.0001 1.66 <.0001
* Adjusted for donor, CMV serostatus, regimen intensity, age, disease risk,
KPS; stratiﬁed on institution.
Figure 1. Associations between biomarker values (A, ferritin [Fer]; B, albumin
[Alb]; and C, platelets [Plt]) and cumulative incidence of NRM in the combined
cohort of all patients.
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(40%) had HCT-CI scores of 0, with 31%, 14%, and 15% having
HCT-CI scores of 1 to 2, 3, and4, respectively. In all, pre-HCT
ferritin concentrations were available for 1126 patients.
Serum albumin concentrations and platelet counts were
available for 3861 and 3731 patients, respectively. Patient
characteristics are shown in Table 1.
Associations between Individual Biomarkers and NRM
and OS
To ensure reproducibility across institutions, we elected
to perform an initial analysis within the FHCRC population
(n ¼ 1758). In that multivariate model accounting for all 5
biomarkers, the HCT-CI, and other variables, only ferritin
>1000 mg/dL (HR 1.98; P ¼ .0003) and >2500 mg/dL (HR
1.97; P¼ .0005), albumin<3.5 g/dL (HR 1.63; P< .00001) and
<3.0 g/dL (HR 1.73; P< .0001), and platelet counts<100,000/
mL (HR 1.65; P< .0001),<50,000/mL (HR 1.52; P< .0001), and<20,000/mL (HR 1.54; P < .008) remained independently
associated with NRM. Hgb and ANC values did not have
statistically signiﬁcant associations with NRM in these
models.
Results were then validated in a larger population of pa-
tients from DFCI and GITMO. In multivariate models,
adjusted for the previously mentioned variables, ferritin
>2500 and incremental decreases in albumin and platelets
counts had statistically signiﬁcant associations with both
NRM and survival (Table 2). Of note, HCT-CI scores (2, 3, and
4) also retained statistically signiﬁcant associations with
NRM and survival in the presence of the 3 biomarker values
in both the initial FHCRC and combined DFCI/GITMO cohorts.
Figure 1 shows the association between serum ferritin,
serum albumin, and platelet count with NRM in the com-
bined cohort, which includes all 3 institutions (n ¼ 3917).
Table 3
Multivariate Analyses for Associations between Biomarker Values and Risks
of NRM within the Training Set (n ¼ 2352)*
Biomarker/cutoff values n HR (95% CI) P
Albumin  3.5 1525 1.0
Albumin < 3.5-3.0 430 1.61 (1.31-1.99) <.0001
Albumin < 3.0 169 2.27 (1.73-2.98) <.0001
Albumin unknown 189 1.09 (.80-1.49) .59
Platelets  100K 1330 1.0
Platelets < 100K-50K 428 1.28 (1.03-1.58) .02
Platelets < 50K-20K 310 1.29 (1.01-1.65) .04
Platelets < 20K 186 1.55 (1.16-2.07) .003
Platelets unknown 59 .80 (.45-1.40) .43
Ferritin  1000 550 1.0
Ferritin > 1000-2500 393 .96 (.73-1.27) .78
Ferritin > 2500 183 1.69 (1.25-2.29) .0006
Ferritin unknown 1187 1.19 (.95-1.50) .14
* Adjusted for donor (related, unrelated), patient CMV serostatus (, þ),
regimen intensity (myeloablative, RIC/NMA), age (<50, 50), disease risk
(low, high), KPS (>90, 90), HCT-CI (0, 1, 2, 3, 4); stratiﬁed on institution.
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training set (n ¼ 2352) and a validation set (n ¼ 1407). In the
training set, albumin <3.5 g/dL and <3.0 g/dL; platelet
counts<100,000,<50,000, and<20,000; and ferritin>2500
mg/dL had statistically signiﬁcant associations with NRM
(Table 3).Incorporation of the Biomarker Values with the HCT-CI in
an Augmented Model
Each of the 3 biomarker values, ferritin 2500 mg/dL,
albumin 3.0 to<3.5 g/dL, and platelet counts<100,000, were
subsequently assigned a weight of 1, whereas albumin <3.0
g/dL was assigned a weight of 2 following the same equation
used to develop the HCT-CI (Table 4) [7].Table 4
Augmented HCT-CI Comorbidities and Their Corresponding Scores
Comorbidity Deﬁnition
Arrhythmia Any type of arrhythmia that has necessitated
any time point in the patient’s past medical h
Cardiac Coronary artery disease,* congestive heart fa
Inﬂammatory bowel disease Crohn’s disease or ulcerative colitis requiring
Diabetes Requiring treatment with insulin or oral hyp
of conditioning
Cerebrovascular disease Transient ischemic attack or cerebrovascular
Psychiatric disturbance Any disorder requiring continuous treatment
Hepatic, mild Chronic hepatitis, bilirubin > ULN to 1.5  U
within 2 or 4 weeks before start of condition
Obesity Patients with a BMI > 35 kg/m2 for patients >
for patients  18 years
Infection Requiring antimicrobial treatment starting fr
High ferritin Values  2500 as measured the closest befor
Mild hypoalbuminemia Values < 3.5-3.0 as measured the closest befo
Thrombocytopenia Values < 100,000 as measured the closest be
Rheumatologic Requiring speciﬁc treatment at any time poin
Peptic ulcer Based on prior endoscopic or radiologic diagn
Moderate/severe renal Serum creatinine > 2 mg/dL (2 values of ea
on dialysis, or before renal transplantation
Moderate pulmonary Corrected DLCO (via Dinakara equation) and/o
Moderate hypoalbuminemia Values < 3.0 as measured the closest before s
Prior malignancy Treated at any time point in the patient’s pas
Heart valve disease Of at least moderate severity, prosthetic valv
by echocardiogram
Severe pulmonary Corrected DLCO (via Dinakara equation) and/o
Moderate/severe hepatic Liver cirrhosis, bilirubin > 1.5  ULN, or AST/
2 or 4 weeks before start of conditioning
ULN indicates upper limit of normal; AST/ALT, aspartate and alanine aminotransfe
FEV1, forced expiratory volume in 1 second.
* One or more vessel-coronary artery stenosis requiring medical treatment, stenIn the validation set, we conﬁrmed that ferritin >2500
mg/dL, albumin <3.0 and 3.0 to <3.5 g/dL, and platelet
counts <100,000 stratiﬁed cumulative incidences of NRM
well (Figure 2). Weights were then assigned to each of the 3
biomarkers (ferritin, albumin, and platelet counts) and
added to those of the HCT-CI to compute the augmented
HCT-CI score for each patient. Although 41%, 32%, 20%, and 7%
of patients had HCT-CI scores of 0, 1 to 2, 3 to 4, and 5,
respectively, the corresponding percentages for augmented
HCT-CI scores of 0, 1 to 2, 3 to 4, and 5 were 22%, 38%, 24%,
and 16%, respectively (Figure 3). The augmented model had a
higher c-statistic estimate (.61) for prediction of NRM
compared with the HCT-CI alone (.58) when measured as a
continuous variable. This difference was statistically signiﬁ-
cant (P ¼ .0007).
With the use of the augmented HCT-CI scores, patients
were stratiﬁed into 4 risk groups of scores of 0, 1 to 2, 3 to 4,
and 5 for rates of NRM and survival. In adjusted multivar-
iate models, patients with scores of 1 to 2, 3 to 4, and 5 had
HRs of 1.05 (95% conﬁdence interval [CI], .9 to 1.3), 1.35 (95%
CI, 1.1 to 1.7), and 2.13 (95% CI, 1.7 to 2.7), respectively, for
NRM comparedwith thosewith score 0. For OS, the HRswere
1.13 (95% CI, .9 to 1.4), 1.53 (95% CI, 1.2 to 1.9), and 2.74 (95%
CI, 2.2 to 3.5), respectively. Both associations were highly
statistically signiﬁcant with P < .0001 for both outcomes.
DISCUSSION
We elected to test the associations between 3 speciﬁc
biomarkers (ferritin, albumin, and blood cell counts) with
HCT outcomes because they have a track record of being
associated with speciﬁc organ comorbidities and, as shown
in previous studies, have the potential to inﬂuence post-HCT
morbidity and mortality [16,19,24-31]. There were 2 impor-
tant ﬁndings. First, ferritin 2500 mg/dL, albumin 3 to 3.5Score
the delivery of a speciﬁc antiarrhythmia treatment at
istory
1
ilure, myocardial infarction, or ejection fraction  50% 1
treatment at any time point in patient’s past medical history 1
oglycemic agents continuously for 4 weeks before start 1
accident 1
s for 4 weeks before start of conditioning 1
LN, or AST/ALT > ULN to 2.5  ULN; at least 2 values of each
ing
1
18 years or a BMI-for-age  95th percentile 1
om before conditioning and continued beyond day 0 1
e start of conditioning
re start of conditioning
fore to start of conditioning
t in the patient’s past medical history 2
osis 2
ch within 2 or 4 weeks before start of conditioning), 2
r FEV1 of 66%-80% or dyspnea on slight activity 2
tart of conditioning
t history, excluding nonmelanoma skin cancer 3
e, or symptomatic mitral valve prolapse as detected 3
r FEV1  65% or dyspnea at rest or requiring oxygen 3
ALT > 2.5  ULN; at least 2 values of each within 3
rases; BMI, body mass index; DLCO, diffusion capacity of carbon monoxide;
t, or bypass graft.
Figure 2. Associations between biomarker values (A, ferritin [Fer]; B, albumin
[Alb]; and C, platelets [Plt]) and cumulative incidences of NRM in the valida-
tion set.
Figure 3. Distribution of HCT-CI and augmented HCT-CI scores.
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pendently associated with increased risks of NRM and
overall mortality after allogeneic HCT. This ﬁnding was
conﬁrmed in 2 distinct sensitivity analyses: 1 testing their
performance characteristics in 2 independent center-speciﬁc
(FHCRC versus DFCI/GITMO) cohorts and the other in 2
randomly selected training and validation sets for weight
assignment. Second, we were able to demonstrate that the
discriminative capacity of the HCT-CI could be improved by
incorporating weights for multiple signiﬁcant objective bio-
markers. This was done by using data from a large groups of
patients treated at multiple centers in 2 different continents
to ensure reproducibility of results.Understanding the biological basis of these associations is
an important area of continuing investigation. Although
multiple studies, in addition to ours, have shown a strong
association between elevated pre-HCT ferritin and increased
risk of NRM mortality [19,20,24,26,27,32] after allogeneic
HCT, the assertion that this relationship is solely due to the
effects of chronic iron overload has been disputed
[20,29,33-35]. One hypothesis is that high levels of ferritin,
an acute phase reactant, may indicate the presence of
inﬂammation and occult tissue injury. Low serum albumin,
although frequently used as a marker of nutritional status or
hepatic function, is also a well-recognized indicator of
chronic inﬂammation. Despite this fact, ferritin and albumin
have independent associations with NRM and OS in our
analysis, suggesting their physiologic contribution to prog-
nosis occurs through at least partially separate mechanisms.
This interpretation is consistent with results of previous
studies showing that adjustment for hypoalbuminemia did
not attenuate the risk of NRM associated with high serum
ferritin concentrations [19]. Other investigators have sug-
gested that high ferritin levels may correlate with the effects
of acute iron toxicity and that pre-HCT transfusion burden
[30] or speciﬁc biomarkers measuring circulating free iron
may serve as more reliable prognostic variables [20,36].
Additional studies are needed to better characterize the
physiologic basis of ferritin’s prognostic impact because it
could have signiﬁcant implications for the incorporation of
iron chelation as part of peri-HCT care [37,38].
Hypoalbuminemia before HCT may reﬂect poor nutri-
tional status and poor hepatic synthetic function, even
though the HCT-CI accounts for elevated serum bilirubin and
transaminase concentrations. Supporting the inference that
the effect of low albumin on outcome is dictated by its cor-
relation with nutritional status are previous studies that
show the importance of pre-HCT nutritional status to OS
after HCT using more speciﬁc measurement tools such as
body mass index, bioimpedance, and anthropometry
[39-41]. As with ferritin, the prognostic value of serum al-
bumin highlights a potential area of intervention (eg,
aggressive nutritional supplementation pre-HCT) that could
be targeted to improve outcome.
Peripheral blood count recovery before HCT is often used
by physicians as a marker of poor marrow reserve after prior
therapies. Thrombocytopenia, in particular, predicts OS after
recovery from induction chemotherapy for acute myeloge-
nous leukemia [16] and after HCT for myelodysplastic
syndrome, independent of disease or cytogenetic risk
[15]. Despite previous studies suggesting that pre-HCT
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larger analysis, low ANC was not associated with increased
risk of NRM after adjusting for HCT-CI and other biomarkers.
Pre-HCT Hgb also showed no association. These results may
suggest that platelet count has a higher sensitivity to the
severity of prior treatment or underlying persistent malig-
nancy, both of which place patients at higher risk of non-
relapse death after HCT. Using a training-validation
approach, we were able to assign scores to the 3 biomarkers
and combine them with the HCT-CI scores in an augmented
model. A statistically signiﬁcant improvement in c-statistic
estimate for NRM was observed after combining the HCT-CI
with biomarkers in the validation set with patients from
multiple institutions and varying practices.
This particular analysis had 2 limitations. First, the
retrospective assignment of HCT-CI scores between the
participating institutions could have been inconsistent. We
believe the improvement in c-statistic could have been more
profound if the data had been collected more consistently
using newly published guidelines (www.hctci.org) [42] and,
preferably, in a prospective fashion. Second, data from some
centers were missing complete information for some of the
biomarkers. Nevertheless, the robust overall sample size and
our careful approach of deﬁning associations in a training set
and then validating ﬁndings in an independent cohort sup-
port generalization of the ﬁndings.
The mechanisms accounting for the association of low
platelet counts and high ferritin and low albumin concen-
trations in the serum with prognosis after allogeneic HCT
have not been deﬁned. Nonetheless, the biomarkers identi-
ﬁed in this large multicenter study warrant consideration
together with the comorbidities captured by the HCT-CI
when the ﬁtness of patients for allogeneic HCT is evaluated.
These laboratory values are readily obtained in the clinic, are
easily interpreted, and can be used to provide prognostic
information to patients and their families. Future studies
should concentrate on determining whether speciﬁc in-
terventions to improve these laboratory values before HCT
will lead to reduced treatment-related mortality and
improved OS.
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